<DOC>
	<DOCNO>NCT01304628</DOCNO>
	<brief_summary>The objective study evaluate single subcutaneous ( SC ) dose PL-3994 , administer patient asthma achieve clinically meaningful increase pulmonary function ( Forced Expiratory Volume one second : FEV1 ) maintain acceptable safety profile . The study characterize bronchodilator effect , dose safety PL-3994 population moderately severe , stable asthmatic follow overnight withdrawal beta-2 agonist .</brief_summary>
	<brief_title>Cross-Over Study Subcutaneous Study Drug Treatment Patients With Mild Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Subject provide write informed consent The subject male female &gt; 18 65 year age Patient clinical history asthma define National Asthma Education Prevention Program . Documented bronchodilator response albuterol define American Thoracic Society ( &gt; 200 mL &gt; 12 % increase FEV1 bronchodilator inhalation ) FEV1 postbronchodilator 55 % 80 % predict . Currently take 2001000 mcg ( fluticasone equivalent ) inhale corticosteroid All inclusion criterion meet within past 12 month . If subject subject 's partner childbearing potential , medically acceptable form contraception use three month prior screen visit ( female ) , duration study one month follow last dose study drug . Medically acceptable contraceptive include : ( 1 ) surgical sterilization , ( 2 ) FDAapproved female hormonal contraceptive , ( 3 ) intrauterine device ( IUD ) , ( 4 ) condom spermicide , ( 5 ) diaphragm spermicide . If subject vasectomy great 6 month prior screen visit , also acceptable . Current diagnosis , per subject investigator screen assessment , : unstable uncontrolled disease organ system ( include cardiovascular ) present therapy psychiatric disease require daily medication , include control uncontrolled schizophrenia uncontrolled psychiatric condition significant neurological disease current history cancer ( except nonmelanomatous skin cancer ) diagnose less 5 year prior screen acute chronic disease require frequent change medication change dosage chronic therapy history alcohol abuse within past 5 year positive result alcohol and/or drug test screen checkin positive HIV , Hep B &amp; C screen blood donation within 30 day screen plasma donation within 7 day screen weight &gt; 100 kg &lt; 50 kg clinically significant electrocardiogram ( ECG ) screen clinically significant ( per investigator ) lab abnormality fever clinically significant physical exam abnormality History COPD lung disease Greater 10 pack per year smoking history cigarette smoking within past 12 month Patients unable withhold bronchodilator treatment 12 hour prior dose Patients hypoxia screen Check Visit 2 , Day 1 Visit 3 , Day 7 ( oxygen saturation measure pulse oximetry [ SpO2 ] &lt; 90 % ) Tachycardia ( heart rate &gt; 100 beats/min ) screen Currently treat Hypertension take medication affect blood pressure significantly . Currently take medication inhibit PDE activity affect cyclic guanisine monophosphate ( cGMP ) pathway ( e.g . theophylline ) . These medication prohibit study least 5 half life prior Checkin Visit 2 , Day 1 Visit 3 , Day 7 cGMP measurement affect . Hypotension ( systolic blood pressure &lt; 110 mmHg ) Screening Checkin Visit 2 , Day 1 Visit 3 , Day 7 Chronic kidney disease define estimate glomerular filtration rate ( eGFR ) &lt; 50 mL/m2 . Diagnosis heart failure history hospitalization congestive heart failure . History coronary artery disease define prior myocardial infarction , prior revascularization procedure , &gt; 50 % coronary artery obstruction angiography . Prior history stroke transient ischemic attack . Female patient childbearing potential nursing positive pregnancy test Screening Check Visit 2 , Day 1 Visit 3 , Day 7 Any major disability disease expect survival less 6 month Administration investigational drug implantation investigational device , participation another trial , within 30 day screen . Inability perform acceptable , quality serial spirometry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>asthma</keyword>
</DOC>